PDS Biotechnology Corp 8-K

What Happened PDS Biotechnology Corporation announced on an 8‑K that on February 25, 2026 it received a deficiency letter from the Nasdaq Listing Qualifications Staff stating the company’s common stock has closed below the $1.00 per‑share minimum required by Nasdaq Listing Rule 5550(a)(2) for the last 30 consecutive business days. The letter does not immediately delist the shares; PDSB will continue trading on The Nasdaq Capital Market under the ticker “PDSB.”

Key Details

• Date of notice: February 25, 2026.
• Deficiency: closing bid price below $1.00 for 30 consecutive business days (Nasdaq Rule 5550(a)(2)).
• Compliance period: 180 calendar days to regain compliance (until August 24, 2026).
• Regain requirement: a closing bid of $1.00 or more for at least 10 consecutive business days during the compliance period.
• If not regained, the company may be eligible for a second 180‑day period if it meets Nasdaq’s market value of publicly held shares and other initial listing standards (except the minimum bid price) and notifies Nasdaq of intent to cure. The company may consider actions such as a reverse stock split.

Why It Matters This filing signals a listing‑standards issue that could lead to delisting if not corrected. Delisting would likely reduce liquidity and could move the stock to less regulated marketplaces, which can affect shareholder value and trading ease. The company has a defined window to meet Nasdaq’s $1.00 bid requirement or pursue permitted remedies (including a possible reverse stock split); investors should monitor share price, corporate announcements, and any proposed corporate actions.